New Delhi: The Government has been examining the Drugs (Prices Control) Order, 2013 (DPCO) with a view to enhancing the accessibility and affordability of essential medicines at reasonable prices to the poor and needy while providing sufficient opportunity for innovation and competition to support the growth of the Pharmaceutical Industry. The Government has been actively interacting with the Industry and other stakeholders on these issues. Any impression regarding tightening of price control is both misleading and misplaced. This was stated in the statement issued by the Department of Pharmaceuticals, Government of India on 20th October.
Under the provisions of DPCO, the prices of only those medicines are fixed which are in the National List of Essential Medicines (NLEM), numbering about 850 against more than 6,000 medicines available in the market of various strengths and dosages. This constitutes approximately 17 percent of the total pharmaceuticals market, in value terms. There is an Expert Committee which continuously evaluates the list of Essential Medicines.
Important issues under consideration of the Department are i) treating the drugs which have become non-scheduled as non-scheduled drugs without any freezing of their prices for a further year; ii) revision of the list of scheduled medicines on the basis of revision of NLEM by incorporating only additions and deletions to the list so that the prices of only ‘’new medicines” which are added to the NLEM will be fixed by NPPA; iii) limiting the determination of overcharged amount of a medicine found to be sold at higher than the ceiling price to the stock available with the defaulter; iv) In case of negative WPI, mandating the NPPA to change the ceiling price of scheduled drugs and not require the individual drugs to also reduce their MRPs if they are already lower than such revised ceiling price; etc. Other issues include new provisions for using Institutional price data for fixation of prices of those scheduled medicines which are being supplied directly to the Healthcare Institutions.
The Department of Pharmaceuticals also clarified that any changes in the methodology of calculating ceiling prices of scheduled medicines are presently not under consideration.